ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026)

ARS Pharmaceuticals has reported Free Cash Flow for 7 years, with the latest figure at -$44.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 10.07% year-over-year to -$44.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175.3 million (down 732.67% YoY) and the FY2025 annual result came in at -$171.2 million, down 1418.48% from the prior year.
• Free Cash Flow eased to -$44.9 million in Q1 2026 per SPRY's latest filing, from -$43.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $41.7 million in Q4 2024 and troughed at -$45.4 million in Q2 2025.
• A 5-year average of -$17.8 million and a median of -$14.7 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 338.45% in 2024, then plunged 530.36% in 2025.
• Over 5 years, Free Cash Flow stood at -$20.6 million in 2022, then grew by 15.2% to -$17.5 million in 2023, then soared by 338.45% to $41.7 million in 2024, then sank by 204.28% to -$43.5 million in 2025, then declined by 3.36% to -$44.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$44.9 million, -$43.5 million, and -$41.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.